We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The Effect of Paricalcitol on Vascular Calcification and Cardiovascular Disease in Uremia: Beyond PTH Control.
- Authors
Cozzolino, Mario; Mehmeti, Florjan; Ciceri, Paola; Volpi, Elisa; Stucchi, Andrea; Brenna, Irene; Cusi, Daniele
- Abstract
Secondary hyperparathyroidism is a systemic disorder that associates with bone and cardiovascular disease, including arterial calcification. Treatment with calcitriol, the active form of vitamin D, reduces parathyroid hormone levels, but may result in elevations in serum calcium and phosphorus, increasing the risk of vascular calcification in dialysis patients. New vitamin D receptor activators (VDRAs) have been developed and investigated with the rationale to treat high serum PTH levels, with a reduced risk of hypercalcemia and hyperphosphatemia. Paricalcitol is a selective VDRA that suppresses PTH secretion with minimal increases on serum calcium and phosphate. Moreover, paricalcitol prevents vascular calcification in experimental models of renal failure, compared with calcitriol.
- Subjects
CALCITRIOL; CALCINOSIS; CARDIOVASCULAR diseases; HYPERPARATHYROIDISM; UREMIA; PREVENTION; THERAPEUTICS
- Publication
International Journal of Nephrology, 2011, p1
- ISSN
2090-214X
- Publication type
Article
- DOI
10.4061/2011/269060